Results 201 to 210 of about 1,254,012 (356)

Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients. [PDF]

Cancer Immunol Immunother
Oliver J, Reed H, Capitani L, Poon-King A, Young A, Milutinovic S, Kuczynski M, Nicholas O, Rackley T, Pembroke C, Godkin A, Gallimore AM.   +11 more
europepmc   +1 more source

Association Between rs2736109 and Progression—Free Survival.

, 2015
Xueying Zhao, Shiming Wang, Junjie Wu, M Kellis, Xun Wang, Zhiqiang Gao, Wenting Wu, Haijian Wang, Jiucun Wang, Qian Ji, Ke Ma, Li Hui, Baohui Han, Bai Chunxue, Li Qiang, Wenbin Liu, Lu Daru   +16 more
openalex   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility

South Asian Journal of Cancer
Santosh Kumar Swain, Lalatendu Moharana, Ghanashyam Biswas, Lipsita Samantaray, Ayush Dubey, Reetu Singhal, Bhavya Inimerla, Antara Sanyal, Swati Sucharita Mohanty, Soumya Surath Panda   +9 more
doaj   +1 more source

MRI-based Habitat Analysis for the Prediction of Progression-Free Survival in Primary Spinal Tumors. [PDF]

Radiology
Wang Q, Zhang Y, Wang T, Chen Y, Yan R, Liu K, Zhao W, Hao D, Su MY, Lang N.   +9 more
europepmc   +1 more source

Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial

, 2017
Christian Marth
openalex   +2 more sources

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naïve metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Castro E, Paganelli S, Wang D, Haltner A, Niyazov A, Chang J, Samjoo IA, Barata PC.   +7 more
europepmc   +1 more source

Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? [PDF]

, 2015
Marta Bonotto, Lorenzo Gerratana, Donatella Iacono, Alessandro Marco Minisini, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi   +6 more
openalex   +1 more source

PET/CT radiomics potentially improves progression-free survival (PFS) and overall survival (OS) prognostication beyond UICC TNM staging in oropharyngeal squamous cell carcinoma (OPSCC) patients

, 2022
Stefan P. Haider, Kariem Sharaf, Tal Zeevi, Amit Mahajan, Reza Forghani, Benjamin L. Judson, Benjamin H. Kann, Barbara Burtness, Christoph A. Reichel, Philipp Baumeister, Seyedmehdi Payabvash   +10 more
openalex   +1 more source